Scailyte Strengthens Its Leadership with Key Appointments

BASEL, SWITZERLAND / ACCESSWIRE / July 8, 2024 / Scailyte, a pioneer in single-cell and AI-driven biomarker discovery, has announced the addition of three new members to its leadership team and Board of Directors as the company continues its expansion in North America.

Tim Foley, based in Chicago, has been appointed as Chief Business Officer. With two decades of experience at Takeda, Astellas, and emerging AI/ML life science startups, Foley brings extensive knowledge in strategic leadership and biomarker-driven drug development. His strategic vision and hands-on approach will be essential for Scailyte's growth.

Dr. Jean-Pierre Rosat, General Partner at 4FOX ventures, becomes Executive Chair. Rosat, a seasoned medtech entrepreneur and co-founder of a medtech and AI-focused venture fund, will support Scailyte with fundraising and strategic initiatives.

Darrin Crisitello, Chief Commercial Officer of Quanterix, joins the Board of Directors. Crisitello has a robust background in the diagnostics and life science industry, with significant contributions to the commercial growth of companies like Mission Bio, Natera, and Color Health.

Scailyte's CEO, Peter Nestorov, expressed his excitement about the new appointments, highlighting their contributions to advancing precision medicine through single-cell multi-omics analysis and artificial intelligence.